FY2025 · ended Dec 31, 2025 · Revenue $7.50M, -20.5% YoY · Filed Feb 26, 2026
Xenon Pharmaceuticals Inc. (XENE) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $7.5 million and a net loss of $345.9 million. Free cash flow was -$279.9 million. As of Jun 30, 2026 it held $1.2 billion in cash and investments and $6.4 million in total debt.
Revenue (TTM)
$0
Net income (TTM)
$-409.19M
-47.1% vs year-ago TTM
Operating cash flow (TTM)
$-337.52M
-46.8% vs year-ago TTM
Free cash flow (TTM)
$-338.53M
-46.2% vs year-ago TTM
EPS (TTM)
$-4.73
-33.4% vs year-ago TTM
Dividend per share
None
Shares outstanding
83.19M
+8.7% vs prior year
Net cash
$1.24B
as of Jun 30, 2026
Operating margin
-4974.3%
FY 2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- XENE (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- British Columbia, Canada
- Headquarters
- Burnaby
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1582313
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $7.5M | — | — | $9.4M | $18.4M |
| Operating income | -$373.1M | -$279.3M | -$214.1M | -$129.1M | -$79.0M |
| Net income | -$345.9M | -$234.3M | -$182.4M | -$125.4M | -$78.9M |
| Diluted EPS | -$4.36 | -$3.01 | -$2.73 | -$2.06 | — |
| Operating cash flow | -$279.1M | -$181.4M | -$151.1M | -$101.0M | -$69.5M |
| Free cash flow | -$279.9M | -$184.5M | -$156.7M | -$103.9M | -$71.6M |
| Total assets | $633.2M | $798.1M | $964.8M | $754.1M | $572.0M |
| Total liabilities | $51.4M | $43.2M | $36.9M | $32.6M | $22.0M |
| Stockholders' equity | $581.8M | $754.9M | $927.9M | $721.5M | $550.0M |
| Cash and investments | $586.0M | $754.4M | $930.9M | $720.8M | $551.8M |
| Total debt | $7.9M | $9.0M | $10.9M | $10.4M | $8.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 3, 2026 | Jun 2, 2026 |
| 10-Q | Quarterly report | May 7, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 7, 2026 | May 7, 2026 |
| ARS | Annual report to shareholders | Apr 22, 2026 | Dec 31, 2025 |
All 800 Xenon Pharmaceuticals Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.